Incidence of inflammatory bowel disease in patients with ankylosing spondylitis

• Published in: Annals of the rheumatic diseases Vol. 80; no. 9; p. e144
• Main Authors: Lai, Shih-Wei, Kuo, Yu-Hung, Liao, Kuan-Fu
• Format: Journal Article
• Language: English
• Published: England Elsevier Limited 01.09.2021
• Subjects: Ankylosing spondylitis; Arthritis; Clinical trials; Colitis; Crohn Disease; Humans; Incidence; Inflammatory bowel disease; Inflammatory bowel diseases; Inflammatory Bowel Diseases - complications; Inflammatory Bowel Diseases - epidemiology; Intestine; Pathogenesis; Patients; Psoriasis; Psoriatic arthritis; Spondylitis, Ankylosing - complications; Spondylitis, Ankylosing - epidemiology; Taiwan; epidemiology; Inflammation; ankylosing spondylitis
• ISSN: 0003-4967; 1468-2060; 1468-2060
• DOI: 10.1136/annrheumdis-2019-216362

The association between ankylosing spondylitis and other diseases has been extensively assessed.1 2 Recently a cohort study conducted by Schreiber et al published in Annals of the Rheumatic Diseases found that the new-onset cases of inflammatory bowel disease were uncommon in patients with ankylosing spondylitis on secukinumab therapy (1.13%, 9/794).3 In order to examine the association between ankylosing spondylitis and inflammatory bowel disease in a different country, a preliminary cohort study was undertaken using the 2005–2012 database of the Taiwan National Health Insurance Programme with 23 million residents living in Taiwan.4 Subjects ages 20–84 with a new diagnosis of ankylosing spondylitis were identified as the ankylosing spondylitis group (International Classification of Diseases, Ninth Revision code (ICD-9 code 720.0)). Table 1 presents that the overall incidence of inflammatory bowel disease was lower in the ankylosing spondylitis group than in the non-ankylosing spondylitis group, but without reaching statistical significance (1.41 vs 1.79 per 1000 person-years, incidence rate ratio 0.79, 95% CI 0.48 to 1.28; p=0.332). Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials.